3D Organoids vs 2D Cell Lines in Drug Discovery and Disease Modeling
This Biocompare article explores the growing shift toward more physiologically relevant 3D models and the challenges that come with scaling them for high-throughput drug screening.
Nikki Carter, Commercial Organoid Innovation Director at Molecular Devices, offers expert insight into how automation, AI-driven analysis, and ready-to-use organoid models are helping researchers overcome key barriers to adoption.